Phaseline

Targets › CAMPATH1

CAMPATH1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2034.

Open in Phaseline: the race on CAMPATH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johns Hopkins UniversityMonoclonal Antibody (Humanized Anti-CD52)
Anti-CD52 monoclonal antibody for immunosuppression
CAMPATH1Phase 2AmputationJun 2034

Conditions

Amputation (1)

Modalities

mixed (1)

Companies

Johns Hopkins University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.